C-Rad AB (publ) (CRAD-B) - Cash Flow Conversion Efficiency

Latest as of December 2025: 0.205x

Based on the latest financial reports, C-Rad AB (publ) (CRAD-B) has a cash flow conversion efficiency ratio of 0.205x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr71.10 Million ≈ $7.65 Million USD) by net assets (Skr347.20 Million ≈ $37.36 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See C-Rad AB (publ) (CRAD-B) defensive interval to measure how many days the company can operate on defensive assets alone.

C-Rad AB (publ) - Cash Flow Conversion Efficiency Trend (2008–2025)

This chart illustrates how C-Rad AB (publ)'s cash flow conversion efficiency has evolved over time, based on yearly financial data.

C-Rad AB (publ) Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of C-Rad AB (publ) ranked by their cash flow conversion efficiency.

Company Cash Flow Conversion Efficiency
American Outdoor Brands Inc
NASDAQ:AOUT
0.060x
Tonlin Department Store Co Ltd
TW:2910
0.020x
Thac Mo Hydropower JSC
VN:TMP
0.122x
Alkim Alkali Kimya AS
IS:ALKIM
0.070x
Donegal Group B Inc
NASDAQ:DGICB
0.016x
Hunter Group ASA
OL:HUNT
-0.134x
Lake Shore Bancorp Inc
NASDAQ:LSBK
0.020x
Paxman AB
ST:PAX
-0.014x

Annual Cash Flow Conversion Efficiency for C-Rad AB (publ) (2008–2025)

The table below shows the annual cash flow conversion efficiency of C-Rad AB (publ) from 2008 to 2025. For the full company profile with market capitalisation and key ratios, see C-Rad AB (publ) (CRAD-B) total market value.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2025-12-31 Skr347.20 Million
≈ $37.36 Million
Skr71.10 Million
≈ $7.65 Million
0.205x +121.28%
2024-12-31 Skr324.99 Million
≈ $34.97 Million
Skr30.08 Million
≈ $3.24 Million
0.093x -21.94%
2023-12-31 Skr281.60 Million
≈ $30.30 Million
Skr33.38 Million
≈ $3.59 Million
0.119x +196.73%
2022-12-31 Skr242.54 Million
≈ $26.10 Million
Skr9.69 Million
≈ $1.04 Million
0.040x -49.18%
2021-12-31 Skr231.09 Million
≈ $24.87 Million
Skr18.17 Million
≈ $1.96 Million
0.079x -14.85%
2020-12-31 Skr199.79 Million
≈ $21.50 Million
Skr18.45 Million
≈ $1.99 Million
0.092x -51.38%
2019-12-31 Skr83.33 Million
≈ $8.97 Million
Skr15.83 Million
≈ $1.70 Million
0.190x +285.14%
2018-12-31 Skr93.64 Million
≈ $10.08 Million
Skr-9.61 Million
≈ $-1.03 Million
-0.103x -82.21%
2017-12-31 Skr71.41 Million
≈ $7.68 Million
Skr-4.02 Million
≈ $-432.62K
-0.056x +91.09%
2016-12-31 Skr70.60 Million
≈ $7.60 Million
Skr-44.62 Million
≈ $-4.80 Million
-0.632x -10.29%
2015-12-31 Skr40.05 Million
≈ $4.31 Million
Skr-22.95 Million
≈ $-2.47 Million
-0.573x -38.13%
2014-12-31 Skr40.04 Million
≈ $4.31 Million
Skr-16.61 Million
≈ $-1.79 Million
-0.415x +30.97%
2013-12-31 Skr38.03 Million
≈ $4.09 Million
Skr-22.86 Million
≈ $-2.46 Million
-0.601x +25.17%
2012-12-31 Skr16.26 Million
≈ $1.75 Million
Skr-13.06 Million
≈ $-1.41 Million
-0.803x -41.62%
2011-12-31 Skr36.02 Million
≈ $3.88 Million
Skr-20.43 Million
≈ $-2.20 Million
-0.567x -444.26%
2010-12-31 Skr48.12 Million
≈ $5.18 Million
Skr-5.01 Million
≈ $-539.60K
-0.104x +64.39%
2009-12-31 Skr29.82 Million
≈ $3.21 Million
Skr-8.73 Million
≈ $-939.06K
-0.293x -2.01%
2008-12-31 Skr35.05 Million
≈ $3.77 Million
Skr-10.06 Million
≈ $-1.08 Million
-0.287x --

About C-Rad AB (publ)

ST:CRAD-B Sweden Medical Devices
Market Cap
$127.56 Million
Skr1.19 Billion SEK
Market Cap Rank
#18352 Global
#315 in Sweden
Share Price
Skr36.90
Change (1 day)
-0.27%
52-Week Range
Skr24.90 - Skr37.00
All Time High
Skr66.70
About

C-Rad AB (publ) develops, manufactures, and sells products and systems with applications in radiotherapy for the treatment of cancer in Europe, the Middle East, Africa, the Americas, and the Asia Pacific. The company offers Catalyst+ HD, a patient positioning, intra-fraction motion management, and respiratory gating solution for conventional and stereotactic treatment delivery; Catalyst+, a solut… Read more